NervGen Doses First Patient in Phase 3 Trial for Chronic Spinal Cord Injury Treatment

  • NervGen has dosed the first participant in its Phase 3 RESTORE study evaluating NVG-291 for chronic cervical motor-incomplete spinal cord injury.
  • The study aims to enroll approximately 150 participants across the U.S. and Canada, with completion anticipated in the second half of 2027.
  • Topline data from the study is expected in the first half of 2028.
  • RESTORE builds on the Phase 1b/2a CONNECT SCI study, with FDA alignment on the registrational design.

NervGen's Phase 3 trial represents a critical step in developing a first-in-class neuroreparative therapeutic for spinal cord injury. The study's focus on functional recovery and independence aligns with broader industry trends toward targeted, regenerative treatments for neurotraumatic conditions. Success in this trial could position NervGen as a leader in this niche, potentially attracting significant investment and partnership opportunities.

Clinical Efficacy
Whether NVG-291 can demonstrate significant improvement in hand function and quality of life for participants.
Regulatory Pathway
The pace at which the FDA will review and potentially approve NVG-291 based on RESTORE study results.
Market Potential
How successful NVG-291 could be in addressing the significant unmet medical need in chronic spinal cord injury treatment.